FINHUB Insights

EW · Q3 FY24 · Jul 1 – Sep 30, 2024

Edwards Lifesciences Q3 FY24: where the revenue came from and where it went

Edwards Lifesciences Q3 FY24: revenue $1.4B (+9% year over year). Net profit $3.1B. Largest cohort Transcatheter Aortic Valve… $1B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2024
Reported
Nov 6, 2024 10-Q
Sankey diagram of Edwards Lifesciences's income statement for Q3 FY24: revenue of $1.4 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.4B +9% year over year
Gross profit$1.1B 81% margin
Operating profit$0.4B 26% margin
Net profit$3.1B 227% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY24 (period ends Sep 30, 2024).
ItemValueShare of revenueYear over year
Revenue 1.4 100% +9%
Transcatheter Aortic Valve… 1 71% +6%
Surgical Heart Valve Therapy 0.2 14% +4%
Transcatheter Mitral and… 0.1 7% +74%
Cost of revenue−0.321%
Gross profit1.181% margin+1pp
Research & development−0.319%−1pp
SG&A−0.431%+0pp
Other−0.15%+0pp
Operating profit0.426% margin−4pp
Net profit3.1227%+196pp
Filing on EDGAR More quarters of EW

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters